Fennec Pharmaceuticals Inc

FENC

Add to Watchlist

9.750USD

+0.510+5.52%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Fennec Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

45 / 155

Overall Ranking

123 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fennec Pharmaceuticals Inc Highlights

StrengthsRisks

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 110.06% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 44.64M.

Undervalued

The company’s latest PE is -33.30, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 18.57M shares, increasing 5.46% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 20.00K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

15.167

Target Price

+64.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Fennec Pharmaceuticals Inc is 7.94, ranking 77 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.11M, representing a year-over-year increase of 72.64%, while its net profit experienced a year-over-year increase of 117.25%.

Score

Industry at a Glance

Previous score

7.94

Change

0



Financials

7.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Fennec Pharmaceuticals Inc is 7.05, ranking 98 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -33.30, which is -434.26% below the recent high of 111.31 and -1219.98% above the recent low of -439.57.

Score

Industry at a Glance

Previous score

7.05

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 45/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Fennec Pharmaceuticals Inc is 8.57, ranking 26 out of 155 in the Pharmaceuticals industry. The average price target is 14.00, with a high of 17.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.67

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Fennec Pharmaceuticals Inc is 9.54, ranking 8 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 11.24 and the support level at 7.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.45

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Fennec Pharmaceuticals Inc is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 53.51%, representing a quarter-over-quarter decrease of 16.42%. The largest institutional shareholder is Steven Cohen, holding a total of 21.30K shares, representing 0.06% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ESSETIFIN S.p.A.

3.99M

--

Southpoint Capital Advisors LP

2.74M

-26.70%

Rosalind Advisors, Inc.

2.61M

+25.84%

Sonic GP LLC

2.61M

+8.31%

Solas Capital Management, LLC

2.56M

+17.04%

AIGH Capital Management, LLC.

1.16M

+130.23%

BlackRock Institutional Trust Company, N.A.

1.11M

+2.16%

AWM Investment Company, Inc.

711.87K

--

Worth Venture Partners, LLC

421.59K

+137.26%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fennec Pharmaceuticals Inc is 3.20, ranking 104 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Fennec Pharmaceuticals Inc

FENC

7.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment